http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Two-Bath Method for Digital Ink-jet Printing of Cotton Fabric with Chitosan
Yuen, C.W.M.,Ku, S.K.A.,Kan, C.W.,Choi, P.S.R. The Korean Fiber Society 2007 Fibers and polymers Vol.8 No.6
In our previous research, the possibility of using chitosan in preparing the pretreatment print paste for digital ink-jet printing for cotton fabric was investigated but the final color was not good as expected. In this paper, we modified our previous work by applying the chitosan separately on the cotton fabric for digital ink-jet printing. A two-bath method was thus proposed and it was confirmed that a better color yield was achieved with this method. However, the use of chitosan reduced the tensile strength of the digital ink-jet printed fabric slightly.
Statistical Tracing of Magnetic Fields: Comparing and Improving the Techniques
Yuen, Ka Ho,Chen, Junda,Hu, Yue,Ho, Ka Wai,Lazarian, A.,Lazarian, Victor,Yang, Bo,Burkhart, Blakesley,Correia, Caio,Cho, Jungyeon,Canto, Bruno,Medeiros, J. R. De American Astronomical Society 2018 The Astrophysical journal Vol.865 No.1
Digital Ink-jet Printing for Chitosan-treated Cotton Fabric
Choi P. S. R.,Yuen C. W. M.,Ku S. K. A.,Kan C. W. The Korean Fiber Society 2005 Fibers and polymers Vol.6 No.3
In this paper, chitosan was suggested for using as a replacement for sodium alginate in the pretreatment print paste for digital ink-jet printing for cotton fabric. Pretreatment print pastes prepared from the mixture of chitosan and acetic acid with the appropriate viscosity gave satisfactory prints on the cotton fabric. Chitosan-treated cotton fabrics were digitally ink-jet printed with four different colors and the color fastness rating of the printed fabrics was satisfactory. Experimental results revealed the possibility of pre-treating the cotton with chitosan to replace the sodium alginate normally present in the pretreatment print paste recipe.
Yu, Jun,Tao, Qian,Cheng, Yuen Y.,Lee, Kwan Y.,Ng, Simon S. M.,Cheung, Kin F.,Tian, Linwei,Rha, Sun Y.,Neumann, Ulf,Rö,cken, Christoph,Ebert, Matthias P. A.,Chan, Francis K. L.,Sung, Joseph J. Y. Wiley Subscription Services, Inc., A Wiley Company 2009 Cancer Vol.115 No.1
<P><B>Abstract</B></P><P><B>BACKGROUND:</B></P><P>Abnormal activation of the Wnt/β‐catenin signaling pathway is common and critical in the pathogenesis of digestive cancers. In this study, the authors investigated the promoter methylation of the dickkopf homolog 3 gene <I>Dkk‐3</I> in these cancers and its prognostic significance in gastric cancer.</P><P><B>METHODS:</B></P><P><I>Dkk‐3</I> methylation was assessed in 173 patients with gastric cancers (including 104 patients who were followed for up to 4090 days) and in 128 patients with colorectal cancer. Cell growth was evaluated by using a colony‐formation assay. For survival analyses, the authors used Kaplan‐Meier plots, the log‐rank test, and Cox proportional regression.</P><P><B>RESULTS:</B></P><P><I>Dkk‐3</I> was silenced or down‐regulated in 12 of 17 gastric cancer cell lines (70.6%) and in 3 of 9 colon cancer cell lines (33.3%). The loss of gene expression was associated with promoter methylation, which could be restored by demethylating agents. Ectopic expression of <I>Dkk‐3</I> suppressed colony formation. Moreover, methylation of <I>Dkk‐3</I> was detected in 117 of 173 primary gastric tumors (67.6%) and in 67 of 128 colorectal tumors (52.3%). The clinical significance and the prognostic value of <I>Dkk‐3</I> methylation also were examined in 104 gastric cancers and in 84 colorectal cancers. Multivariate analysis indicated that <I>Dkk‐3</I> methylation was associated significantly and independently with poor disease survival (relative risk, 2.534; 95% confidence interval, 1.54–4.17; <I>P</I> = .002) in gastric cancer, but not in colorectal cancer. Kaplan‐Meier survival curves revealed that patients who had <I>Dkk‐3</I> methylated gastric cancers had a significantly shorter survival (median, 0.76 years) compared with patients who did not have <I>Dkk‐3</I> methylation (median, 2.68 years; <I>P</I> < .0001; log‐rank test).</P><P><B>CONCLUSIONS:</B></P><P>Epigenetic silencing of the <I>Dkk‐3</I> gene by promoter methylation was a common event in gastric cancer and was associated with a poor outcome in such patients. Cancer 2009. © 2008 American Cancer Society.</P>
Ka Shing Cheung,Lok Ka Lam,Rex Wan Hin Hui,Xianhua Mao,Ruiqi R Zhang,Kwok Hung Chan,Ivan FN Hung,Wai Kay Seto,Man-Fung Yuen 대한간학회 2022 Clinical and Molecular Hepatology(대한간학회지) Vol.28 No.3
Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred ninety-five subjects who received BNT162b2 or CoronaVac vaccines from five vaccination centers were categorized into moderate/severe HS (controlled attenuation parameter ≥268 dB/m on transient elastography) (n=74) or control (n=221) groups. Primary outcomes were seroconversion rates of neutralising antibody by live virus Microneutralization (vMN) assay (titer ≥10) at day21 (BNT162b2) or day28 (CoronaVac) and day56 (both). Secondary outcome was highest-tier titer response (top 25% of vMN titer; cutoff: 160 [BNT162b2] and 20 [CoronaVac]) at day 56. Results: For BNT162b2 (n=228, 77.3%), there was no statistical differences in seroconversion rates (day21: 71.7% vs. 76.6%; day56: 100% vs. 100%) or vMN geometric mean titer (GMT) (day21: 13.2 vs. 13.3; day56: 91.9 vs. 101.4) among moderate/severe HS and control groups respectively. However, lower proportion of moderate/severe HS patients had highest-tier response (day56: 5.0% vs. 15.5%; P=0.037). For CoronaVac (n=67, 22.7%), there was no statistical differences in seroconversion rates (day21: 7.1% vs. 15.1%; day56: 64.3% vs. 83.0%) or vMN GMT (5.3 vs. 5.8,) at day28. However, moderate/severe HS patients had lower vMN GMT (9.1 vs. 14.8, P=0.021) at day 56 with lower proportion having highesttier response (21.4% vs. 52.8%, P=0.036). Conclusions: While there was no difference in seroconversion rate between moderate/severe HS and control groups after two doses of vaccine, a lower proportion of moderate/severe HS patients achieved highest-tier response for either BNT162b2 or CoronaVac.